Restricted accessReview articleFirst published online 2018-12
Efficacy and Harms of Pharmacological Interventions for Neurobehavioral Symptoms in Post-Traumatic Amnesia after Traumatic Brain Injury: A Systematic Review
Many individuals in post-traumatic amnesia (PTA) following traumatic brain injury (TBI) experience neurobehavioral symptoms (NBS) in addition to disorientation and amnesia. These symptoms are associated with low rehabilitation engagement, self-inflicted harm, and risk of violence. The aim of this systematic review was to evaluate the efficacy and harms of pharmacological interventions for NBS in PTA following TBI in adults. Studies in English published before December 2017 were reviewed. Six databases were searched, with additional hand searching of key journals, clinical trials registries, and international drug regulators. Evidence quality was assessed using Joanna Briggs Institute Critical Appraisal Instruments. Thirteen studies were identified: three randomized controlled trials (RCTs), three cohort studies, and seven case series. In the RCTs, neither amantadine nor sertraline reduced NBS. Less rigorous studies reported reduced NBS in patients administered haloperidol, ziprasidone, carbamazepine, amitriptyline, desipramine, and varied neuroleptics. There is a paucity of well-designed, adequately powered and controlled studies of pharmacological interventions for NBS in PTA. More research is needed to provide evidence-based treatment recommendations and improve care.
Get full access to this article
View all access options for this article.
References
1.
WeirN., DoigE.J., FlemingJ.M., WiemersA., and ZemljicC. (2006). Objective and behavioural assessment of the emergence from post-traumatic amnesia (PTA). Brain Inj. 20, 927–935.
2.
MandlebergI.A. (1975). Cognitive recovery after severe head injury. 2. Wechsler adult intelligence scale during post-traumatic amnesia. J. Neurol. Neurosurg. Psychiatry, 38, 1127–1132.
3.
CorriganJ.D. and MysiwW.J. (1988). Agitation following traumatic head injury: Equivocal evidence for a discrete stage of cognitive recovery. Arch. Phys. Med. Rehabil., 69, 487–492.
4.
AhmedS., BierleyR., SheikhJ.I., and DateE.S. (2000). Post-traumatic amnesia after closed head injury: A review of the literature and some suggestions for further research. Brain Inj. 14, 765–780.
5.
PonsfordJ., JanzenS., McIntyreA., BayleyM., VelikonjaD., TateR., and PanelI.E. (2014). Incog recommendations for management of cognition following traumatic brain injury, part i: Posttraumatic amnesia/delirium. J. Head Trauma Rehabil., 29, 307–320.
6.
CorriganJ.D., MysiwW.J., GribbleM.W., and ChockS.K. (1992). Agitation, cognition and attention during post-traumatic amnesia. Brain Inj. 6, 155–160.
7.
CorriganJ.D. and BognerJ.A. (1994). Factor structure of the agitated behavior scale. J. Clin. Exp. Neuropsychol., 16, 386–392.
8.
LequericaA.H., RapportL.J., LoeherK., AxelrodB.N., VangelS.J.Jr., and HanksR.A. (2007). Agitation in acquired brain injury: Impact on acute rehabilitation therapies. J. Head Trauma Rehabil., 22(3), 177–183.
9.
Nygren DeBoussardC., LannsjoM., StenbergM., StalnackeB.M., and GodboltA.K. (2017). Behavioural problems in the first year after severe traumatic brain injury: A prospective multicentre study. Clin. Rehabil., 31, 555–566.
10.
NottM.T., ChapparoC., and BaguleyI.J. (2006). Agitation following traumatic brain injury: An australian sample. Brain Inj. 20, 1175–1182.
11.
McNettM., SarverW., and WilczewskiP. (2012). The prevalence, treatment and outcomes of agitation among patients with brain injury admitted to acute care units. Brain Inj. 26, 1155–1162.
12.
FlanaganS.R., ElovicE.P., and SandelE. (2009). Managing agitation associated with traumatic brain injury: behavioral versus pharmacologic interventions?. PM R, 1, 76–80.
13.
ShutterL.A., and ColohanA.R.T. (1999). Posttraumatic agitation: Psychopharmacology and early management. Neurologist, 5, 258–270.
14.
LombardL.A., and ZafonteR.D. (2005). Agitation after traumatic brain injury: Considerations and treatment options. Am. J. Phys. Med. Rehabil., 84, 797–812.
15.
NejadS.H., ChuangK., HirschbergR., AquinoP.R., and FricchioneG.L. (2014). The use of antiepileptic drugs in acute neuropsychiatric conditions: Focus on traumatic brain injury, pain, and alcohol withdrawal. Int. J. Clin. Med., 5, 724.
16.
BognerJ., BarrettR.S., HammondF.M., HornS.D., CorriganJ.D., RosenthalJ., BeaulieuC.L., WaszkiewiczM., SheaT., ReddinC.J., CullenN., GiuffridaC.G., YoungJ., and GarmoeW. (2015). Predictors of agitated behavior during inpatient rehabilitation for traumatic brain injury. Arch. Phys. Med. Rehabil., 96, 8 Suppl., S274–S281.
17.
BognerJ.A., CorriganJ.D., FugateL., MysiwW.J., and ClinchotD. (2001). Role of agitation in prediction of outcomes after traumatic brain injury. Am. J. Phys. Med. Rehabil., 80, 636–644.
18.
MysiwW.J., and SandelM.E. (1997). The agitated brain injured patient. Part 2: Pathophysiology and treatment. Arch. Phys. Med. Rehabil., 78, 213–220.
19.
SpiesM., KnudsenG.M., LanzenbergerR., and KasperS. (2015). The serotonin transporter in psychiatric disorders: Insights from pet imaging. Lancet Psychiatry, 2, 743–755.
20.
SeyedabadiM., FakhfouriG., RamezaniV., MehrS.E., and RahimianR. (2014). The role of serotonin in memory: Interactions with neurotransmitters and downstream signaling. Exp. Brain Res., 232, 723–738.
21.
DukeA.A., BegueL., BellR., and Eisenlohr-MoulT. (2013). Revisiting the serotonin-aggression relation in humans: a meta-analysis. Psychol. Bull., 139, 1148–1172.
22.
DebS., and CrownshawT. (2004). Review of subject the role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj. 18, 1–31.
23.
Diaz-ArrastiaR., KochanekP.M., BergoldP., KenneyK., MarxC.E., GrimesC.J., LohL.T., AdamL.T., OskvigD., CurleyK.C., and SalzerW. (2014). Pharmacotherapy of traumatic brain injury: State of the science and the road forward: Report of the department of defense neurotrauma pharmacology workgroup. J. Neurotrauma, 31, 135–158.
24.
MortimerD.S., and BergW. (2017). Agitation in patients recovering from traumatic brain injury: nursing management. J. Neurosci. Nurs., 49, 25–30.
25.
FranciscoG.E., WalkerW.C., ZaslerN.D., and BouffardM.H. (2007). Pharmacological management of neurobehavioural sequelae of traumatic brain injury: A survey of current physiatric practice. Brain Inj. 21, 1007–1014.
26.
FugateL.P., SpacekL.A., KrestyL.A., LevyC.E., JohnsonJ.C., and MysiwW.J. (1997). Measurement and treatment of agitation following traumatic brain injury: Ii. A survey of the brain injury special interest group of the american academy of physical medicine and rehabilitation. Arch. Phys. Med. Rehabil., 78, 924–928.
27.
JanzenS., McIntyreA., MeyerM., SequeiraK., and TeasellR. (2014). The management of agitation among inpatients in a brain injury rehabilitation unit. Brain Inj. 28, 318–322.
28.
BhatnagarS., IaccarinoM.A., and ZafonteR. (2016). Pharmacotherapy in rehabilitation of post-acute traumatic brain injury. Brain Res. 1640. 164–179.
29.
Waldron-PerrineB., HanksR.A., and PerrineS.A. (2008). Pharmacotherapy for postacute traumatic brain injury: a literature review for guidance in psychological practice. Rehabil. Psychol., 53, 426–444.
30.
ElovicE.P., LansangR., LiY.L., and RickerJ.H. (2003). The use of atypical antipsychotics in traumatic brain injury. J. Head Trauma Rehabil., 18, 177–195.
31.
ZafonteR.D., CullenN., and LexellJ. (2002). Serotonin agents in the treatment of acquired brain injury. J. Head Trauma Rehabil., 17, 322–334.
32.
HammondF.M., BarrettR.S., SheaT., SeelR.T., McAlisterT.W., KaelinD., RyserD.K., CorriganJ.D., CullenN., and HornS.D. (2015). Psychotropic medication use during inpatient rehabilitation for traumatic brain injury. Arch. Phys. Med. Rehabil., 96, S256–S273.
33.
KimE. (2002). Agitation, aggression, and disinhibition syndromes after traumatic brain injury. NeuroRehabilitation, 17, 297–310.
34.
YoungJ.A. (2012). Pharmacotherapy for traumatic brain injury: focus on sympathomimetics. Pharmacol. Ther., 134, 1–7.
35.
LuauteJ., PlantierD., WiartL., TellL., and SOFMERGroup (2016). Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations. Ann. Phys. Rehabil. Med., 59, 58–67.
36.
SmithK.R.Jr., GouldingP.M., WildermanD., GoldfaderP.R., Holterman-HommesP., and WeiF. (1994). Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: A comparative study. Arch. Neurol., 51, 653–360.
37.
LevineM.J. (2013). Common drug interactions following traumatic brain injury. J. Head Trauma Rehabil., 28, 151–154.
38.
LoE.H., SinghalA.B., TorchilinV.P., and AbbottN.J. (2001). Drug delivery to damaged brain. Brain Res. Rev., 38, 140–148.
39.
Neurobehavioral Guidelines WorkingGroup, WardenD.L., GordonB., McAllisterT.W., SilverJ.M., BarthJ.T., BrunsJ., DrakeA., GentryT., JagodaA., KatzD.I., KrausJ., LabbateL.A., RyanL.M., SparlingM.B., WaltersB., WhyteJ., ZapataA., and ZitnayG. (2006). Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J. Neurotrauma, 23, 1468–1501.
40.
WheatonP., MathiasJ.L., and VinkR. (2011). Impact of pharmacological treatments on cognitive and behavioral outcome in the postacute stages of adult traumatic brain injury: a meta-analysis. J. Clin. Psychopharmacol., 31, 745–757.
41.
Scottish Intercollegiate Guidelines Network (2009). Early Management of Patients with a Head Injury: A National Clinical Guideline. NHS, Edinburgh, Scotland.
42.
FlemingerS., GreenwoodR.J., and OliverD.L. (2006). Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst. Rev. (4),CD003299.
43.
LevyM., BersonA., CookT., BollegalaN., SetoE., TursanskiS., KimJ., SockalingamS., RajputA., KrishnadevN., FengC., and BhaleraoS. (2005). Treatment of agitation following traumatic brain injury: a review of the literature. NeuroRehabilitation, 20, 279–306.
44.
WheatonP., MathiasJ.L., and VinkR. (2009). Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: A meta-analysis. J. Clin. Psychopharmacol., 29, 468–477.
45.
KalraI.D. and WatanabeT.K. (2017). Mood stabilizers for traumatic brain injury-related agitation. J. Head Trauma Rehabil., 32, E61–E64.
46.
AubutJ.-A., BayleyM., LeeT., JanzenS., and TeasellR. (2014). Neuropharmacological interventions post ABI, in: Evidence Based Review of Moderate to Severe Acquired Brain Injury. Parkwood Institute: London, pps. 1–111.
47.
ReesL., JanzenS., AndersonR., WeiserM., TeasellR., and MarshallS. (2016). Mental health issues post ABI, in: Evidence Based Review of Moderate to Severe Acquired Brain Injury. Parkwood Institute: London, pps. 1–92.
48.
MehtaS., McIntyreA., JanzenS., IruthayarajahJ., BatemanA., and TeasellR. (2018). Pharmacological management of agitation among individuals with moderate to severe acquired brain injury: a systematic review. Brain Inj. 32, 287–296.
49.
NoeE., FerriJ., TrenorC., and ChirivellaJ. (2007). Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia. Behav. Neurol., 18, 7–11.
50.
BayleyM., TeasellR., MarshallS., CullenN., ColantonioA., and KuaA. (2007). Abikus Evidence Based Recommendations for Rehabilitation of Moderate to Severe Acquired Brain Injury. Ontario Neurotrauma Foundation: Toronto.
51.
MoherD. (2009). Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann. Intern. Med., 151, 264.
52.
LiberatiA., AltmanD.G., TetzlaffJ., MulrowC., GøtzscheP.C., IoannidisJ.P., ClarkeM., DevereauxP.J., KleijnenJ., and MoherD. (2009). The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 6, e1000100.
53.
BellerE.M., GlasziouP.P., AltmanD.G., HopewellS., BastianH., ChalmersI., GotzscheP.C., LassersonT., ToveyD., for the PRISMA AbstractsGroup. (2013). Prisma for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med. 10(4),e1001419.
54.
AtkinsonK.M., KoenkaA.C., SanchezC.E., MoshontzH., and CooperH. (2015). Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate. Res. Synth. Methods, 6, 87–95.
55.
HicksA.J., ClayF.J., HopwoodM., JayaramM., BattyR., and PonsfordJ.L. (2017). Efficacy and harms of pharmacological interventions for neurobehavioral symptoms in post traumatic amnesia after traumatic brain injury: a systematic review and meta-analysis protocol. JBI Database System Rev. Implement. Rep., 15, 2890–2912.
56.
LevinH.S., O'DonnellV.M., and GrossmanR.G. (1979). The galveston orientation and amnesia test. A practical scale to assess cognition after head injury. J. Nerv. Ment. Dis., 167, 675–684.
57.
MarosszekyN.E.V., RyanL., ShoresE.A., BatchelorJ., and MarosszekyJ.E. (1998).The PTA Protocol: Guidelines for Using The Westmead Post-Traumatic Amnesia (PTA) Scale. Wild & Woolley: Westmead.
58.
JacksonW.T., NovackT.A., and DowlerR.N. (1998). Effective serial measurement of cognitive orientation in rehabilitation: the orientation log. Arch. Phys. Med. Rehabil., 79, 718–720.
59.
SandelM.E., and MysiwW.J. (1996). The agitated brain injured patient. Part 1: Definitions, differential, diagnosis, and assessment. Arch. Phys. Med. Rehabil. 77, 617–623.
60.
The Joanna Briggs Institute (2014). Joanna Briggs Institute Reviewers' Manual: 2014 Edition. The Joanna Briggs Institute: Adelaide, Australia.
61.
MerlinT., WestonA., TooherR., MiddletonP., SalisburyJ., and ColemanK. (2009). NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines. National Health and Medical Research Council (NHRMC): Canberra.
62.
XuS., and LorberM.F. (2014). Interrater agreement statistics with skewed data: Evaluation of alternatives to cohen's kappa. J. Consult. Clin. Psychol., 82(6), 1219–1227.
63.
MeythalerJ.M., DepalmaL., DevivoM.J., Guin-RenfroeS., and NovackT.A. (2001). Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj. 15, 321–331.
64.
MeythalerJ.M., BrunnerR.C., JohnsonA., and NovackT.A. (2002). Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J. Head Trauma Rehabil., 17, 300–313.
65.
Chatham-ShowalterP.E. (1996). Carbamazepine for combativeness in acute traumatic brain injury. J. Neuropsychiatry Clin. Neurosci., 8, 96–99.
66.
RaoN., JellinekH.M., and WoolstonD.C. (1985). Agitation in closed head injury: Haloperidol effects on rehabilitation outcome. Arch. Phys. Med. Rehabil., 66, 30–34.
67.
JacksonR.D., and MysiwW.J. (1989). Abnormal cortisol dynamics after traumatic brain injury – lack of utility in predicting agitation or therapeutic response to tricyclic antidepressants. Am. J. Phys. Med. Rehabil., 68, 18–23.
68.
HarmsenM., GeurtsA.C., FasottiL., and BevaartB.J. (2004). Positive behavioural disturbances in the rehabilitation phase after severe traumatic brain injury: an historic cohort study. Brain Inj. 18, 787–796.
69.
MysiwW.J., JacksonR.D., and CorriganJ.D. (1988). Amitriptyline for post-traumatic agitation. Am. J. Phys. Med. Rehabil., 67, 29–33.
70.
Tapia-PerezJ.H., Sanchez-AguilarM., Torres-CorzoJ.G., Gordillo-MoscosoA., Martinez-PerezP., MadevilleP., de la Cruz-MendozaE., and Chalita-WilliamsJ. (2008). Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (nct00329758). J. Neurotrauma, 25, 1011–1017.
71.
AndersonR.L., BirrerK.L., and Liu-DeRykeX. (2016). Haloperidol use in acute traumatic brain injury: a safety analysis. J. Intensive Crit. Care, 2, 1–6.
72.
GurinL., RabinowitzL., and BlumS. (2016). Predictors of recovery from posttraumatic amnesia. J. Neuropsychiatry Clin. Neurosci., 28, 32–37.
73.
MysiwW.J., BognerJ.A., CorriganJ.D., FugateL.P., ClinchotD.M., and KadyanV. (2006). The impact of acute care medications on rehabilitation outcome after traumatic brain injury. Brain Inj. 20, 905–911.
74.
RosatiD.L. (2002). Early polyneuropharmacologic intervention in brain injury agitation. Am. J. Phys. Med. Rehabil., 81, 90–93.
75.
LandisJ.R., and KochG.G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.
76.
YablonS., ShererM., Nakase-RichardsonR., and ToddN. (2010). Amantadine hydrochloride for treatment of symptoms of the posttraumatic confusional state: a randomized, double-blind, placebo-controlled trial. Arch. Phys. Med. Rehabil., 91, e8–e9.
77.
HoffmanA.N., ChengJ.P., ZafonteR.D., and KlineA.E. (2008). Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits. Life Sci. 83, 602–607.
78.
PhelpsT.I., BondiC.O., AhmedR.H., OlugbadeY.T., and KlineA.E. (2015). Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits. J. Neurotrauma, 32(8), 590–597.
79.
WilsonM.S., GibsonC.J., and HammR.J. (2003). Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am. J. Phys. Med. Rehabil., 82, 871–879.
80.
FeeneyD.M., GonzalezA., and LawW.A. (1982). Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science, 217, 855–857.
81.
GoldsteinL.B., and BullmanS. (2002). Differential effects of haloperidol and clozapine on motor recovery after sensorimotor cortex injury in rats. Neurorehabil. Neural Repair, 16, 321–325.
82.
WilsonM.S., GibsonC.J., and HammR.J. (2003). Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am. J. Phys. Med. Rehabil., 82, 871–879.
83.
RiefW., BarskyA., BingelU., DoeringB., SchwartingR., WöhrM., and SchweigerU. (2016). Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. Neurosci. Biobehav. Rev. 60. 51–64.
84.
FriedlandD., and SwashM. (2016). Post-traumatic amnesia and confusional state: Hazards of retrospective assessment. J. Neurol. Neurosurg. Psychiatry, 87, 1068–1074.
85.
KempS., AgostinisA., HouseA., and CoughlanA.K. (2010). Analgesia and other causes of amnesia that mimic post‐traumatic amnesia (PTA): a cohort study. J. Neuropsychol., 4, 231–236.
86.
McCarterR.J., WaltonN.H., MooreC., WardA., and NelsonI. (2007). Pta testing, the westmead post traumatic amnesia scale and opiate analgesia: a cautionary note. Brain Inj. 21, 1393–1397.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
